Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M G Murphy

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Veterinary Parasitology|August 15, 2000
Evaluation of the effects of selamectin against adult and immature stages of fleas (Ctenocephalides felis felis) on dogs and catsT L McTier, D J Shanks, A D Jernigan, et al.
Skin Pharmacology : the Official Journal of the Skin Pharmacology Society|January 1, 1988
Outward transcutaneous chemical migration: implications for diagnostics and dosimetryC C Peck, D P Conner, B J Bolden, et al.
Journal of Psychopharmacology (Oxford, England)|September 6, 2011
The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcoholS L de Haas, R W M Zoethout, K Van Dyck, et al.
Veterinary Parasitology|August 15, 2000
Efficacy of selamectin against experimentally induced and naturally acquired ascarid (Toxocara canis and Toxascaris leonina) infections in dogsT L McTier, E M Siedek, R G Clemence, et al.
Journal of Psychopharmacology (Oxford, England)|January 12, 2008
Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteersS L de Haas, S J de Visser, J P van der Post, et al.
Journal of Psychopharmacology (Oxford, England)|February 12, 2010
MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humansJ R Atack, K A Wafford, L J Street, et al.
Clinical Pharmacology and Therapeutics|January 27, 2012
A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable anginaB R Chaitman, A P Ho, M O Behm, et al.
Journal of Psychopharmacology (Oxford, England)|November 10, 2006
Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteersS L de Haas, S J de Visser, J P van der Post, et al.
Clinical Pharmacology and Therapeutics|June 29, 2012
Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imagingK Van Laere, J De Hoon, G Bormans, et al.
Journal of Psychopharmacology (Oxford, England)|February 17, 2010
Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonistJ R Atack, D J Hallett, S Tye, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Veterinary Parasitology|August 15, 2000
Evaluation of the effects of selamectin against adult and immature stages of fleas (Ctenocephalides felis felis) on dogs and catsT L McTier, D J Shanks, A D Jernigan, et al.
Skin Pharmacology : the Official Journal of the Skin Pharmacology Society|January 1, 1988
Outward transcutaneous chemical migration: implications for diagnostics and dosimetryC C Peck, D P Conner, B J Bolden, et al.
Journal of Psychopharmacology (Oxford, England)|September 6, 2011
The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcoholS L de Haas, R W M Zoethout, K Van Dyck, et al.
Veterinary Parasitology|August 15, 2000
Efficacy of selamectin against experimentally induced and naturally acquired ascarid (Toxocara canis and Toxascaris leonina) infections in dogsT L McTier, E M Siedek, R G Clemence, et al.
Journal of Psychopharmacology (Oxford, England)|January 12, 2008
Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteersS L de Haas, S J de Visser, J P van der Post, et al.
Journal of Psychopharmacology (Oxford, England)|February 12, 2010
MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humansJ R Atack, K A Wafford, L J Street, et al.
Clinical Pharmacology and Therapeutics|January 27, 2012
A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable anginaB R Chaitman, A P Ho, M O Behm, et al.
Journal of Psychopharmacology (Oxford, England)|November 10, 2006
Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteersS L de Haas, S J de Visser, J P van der Post, et al.
Clinical Pharmacology and Therapeutics|June 29, 2012
Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imagingK Van Laere, J De Hoon, G Bormans, et al.
Journal of Psychopharmacology (Oxford, England)|February 17, 2010
Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonistJ R Atack, D J Hallett, S Tye, et al.
Pageof 9